retatrutide triple agonist glp-1 gip glucagon receptor The TRIUMPH-1 Phase 3 results just dropped on retatrutide. Here is what the numbers actually say. is a agonist. It targets GLP-1, GIP, and receptors. Ozempic targets one. Mounjaro retatrutide triple agonist glp-1 gip

In liver disease, semaglutide received FDA accelerated approval in August 2025 for metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced fibrosis

For individuals with diabetes, a combined creatinine/cystatin C estimate of eGFR should be considered in settings where the creatinine-based eGFR may be unreliable for an individual (see Table 6) [21] [Grade D, Consensus]

How have Medicaid prescriptions and gross spending on GLP-1s changed in recent years

Multivariate Cox regression analysis was performed using the high-dimensional propensity score (HDPS) to obtain adjusted HR estimates

I was spending $350/month on diabetes medications, blood pressure pills, and cholesterol drugs, says Robert, a Blissful Wellness patient who lost 68 pounds